Diagnosis of prostate cancer via nanotechnological approach

Kang, Benedict J; Jeun, Minhong; Jang, Gun Hyuk; Song, Sang Hoon; Jeong, In Gab; Kim, Choung‐Soo; Searson, Peter C.; Lee, Kwan H.

doi:10.2147/ijn.s91908

Cited by 12 publications

(4 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Nanotechnology-based diagnostic approaches (nanobiosensors) involving various biomarkers in various body fluids. Reproduced from [ 134 ] with permission from DovePress, 2015. …”

Section: Figurementioning

confidence: 99%

Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates

et al. 2020

View full text Add to dashboard Cite

The fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater biocompatibility and active targeting at cancer site. Despite all of the advances made over the years in discovering drugs, methods, and new biomarkers for cancer of the prostate (PCa), PCa remains one of the most troubling cancers among people. Early on, effective diagnosis is an essential part of treating prostate cancer. Prostate-specific antigen (PSA) or serum prostate-specific antigen is the best serum marker widely accessible for diagnosis of PCa. Numerous efforts have been made over the past decade to design new biosensor-based strategies for biomolecules detection and PSA miniaturization biomarkers. The growing nanotechnology is expected to have a significant effect in the immediate future on scientific research and healthcare. Nanotechnology is thus predicted to find a way to solve one of the most and long-standing problem, “early cancer detection”. For early diagnosis of PCa biomarkers, different nanoparticles with different approaches have been used. In this review, we provide a brief description of the latest achievements and advances in the use of nanoparticles for PCa biomarker diagnosis.

show abstract

“… Nanotechnology-based diagnostic approaches (nanobiosensors) involving various biomarkers in various body fluids. Reproduced from [ 134 ] with permission from DovePress, 2015. …”

Section: Figurementioning

confidence: 99%

Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates

et al. 2020

View full text Add to dashboard Cite

show abstract

“…According to the guidelines approved by the US Food and Drug Administration (FDA), a concentration of PSA > 4 ng/mL is considered as the gold standard of prostate cancer in initial screening. However, currently used enzyme-linked immunosorbent assay (ELISA) detection method for PSA shows poor sensitivity and specificity, with approximately 70% false-positive rate (Catalona et al, 1991; Bretton, 1994; Kang B.J. et al, 2015).…”

Section: Application Of Nanotechnology In Prostate Cancermentioning

confidence: 99%

Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling

et al. 2017

View full text Add to dashboard Cite

Prostate cancer is the most common cancer among men worldwide. However, current treatments for prostate cancer patients in advanced stage often fail because of relapse. Prostate cancer stem cells (PCSCs) are resistant to most standard therapies, and are considered to be a major mechanism of cancer metastasis and recurrence. In this review, we summarized current understanding of PCSCs and their self-renewal signaling pathways with a specific focus on Wnt signaling. Although multiple Wnt inhibitors have been developed to target PCSCs, their application is still limited by inefficient delivery and toxicity in vivo. Recently, nanotechnology has opened a new avenue for cancer drug delivery, which significantly increases specificity and reduces toxicity. These nanotechnology-based drug delivery methods showed great potential in targeting PCSCs. Here, we summarized current advancement of nanotechnology-based therapeutic strategies for targeting PCSCs and highlighted the challenges and perspectives in designing future therapies to eliminate PCSCs.

show abstract

“…Nanomaterials have been investigated in the medical field for drugs (Cao et al, 2014; Ranganathan et al, 2012; Tan et al, 2011; Zhao et al, 2013) and genes carriers (Banizs et al, 2014; Eroglu et al, 2013; Liu et al, 2014), cancer therapy (Frank et al., 2014; Jabir et al., 2012; Marques et al, 2014; Wang et al, 2013), gene therapy (Rodriguez-Gascon et al, 2014), antibacterial agents (Amrol, 2007; Seil and Webster, 2012; Taylor and Webster, 2011), antiviral agents (du Toit et al, 2010; Mahajan et al, 2012; Parboosing et al, 2012), tissue engineering (Mazaheri et al., 2015; Partha and Conyers, 2009; Tautzenberger et al., 2012; Tonelli et al, 2012), medical diagnosis (Chen et al, 2013; Kang et al, 2015; Madani et al, 2013), medical imaging (Cao et al, 2014; Peng et al, 2008; Sheng et al, 2014; Yi et al, 2014), etc., which bring many benefits to humans. At the same time, studies on the biosafety of nanomaterials have been soaring in recent years (Vega-Villa et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Potential applications and human biosafety of nanomaterials used in nanomedicine

Bowman

et al. 2017

J of Applied Toxicology

138

View full text Add to dashboard Cite

With the rapid development of nanotechnology, potential applications of nanomaterials in medicine have been widely researched in recent years. Nanomaterials themselves can be used as image agents or therapeutic drugs, and for drug and gene delivery, biological devices, nanoelectronic biosensors or molecular nanotechnology. As the composition, morphology, chemical properties, implant sites as well as potential applications become more and more complex, human biosafety of nanomaterials for clinical use has become a major concern. If nanoparticles accumulate in the human body or interact with the body molecules or chemical components, health risks may also occur. Accordingly, the unique chemical and physical properties, potential applications in medical fields, as well as human biosafety in clinical trials are reviewed in this study. Finally, this article tries to give some suggestions for future work in nanomedicine research.

show abstract

Diagnosis of prostate cancer via nanotechnological approach

Cited by 12 publications

References 191 publications

Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates

Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates

Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling

Potential applications and human biosafety of nanomaterials used in nanomedicine

Contact Info

Product

Resources

About